Massachusetts General Hospital is running a clinical trial to test a drug called Blinatumomab to treat Non-Hodgkin Lymphoma. This research study is studying Blinatumomab as a possible treatment for Indolent Non-Hodgkin Lymphoma (NHL).
The drug is Blinatumomab.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 28 participants |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase II Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma |
| Actual Study Start Date : | August 2016 |
| Estimated Primary Completion Date : | December 2019 |
| Estimated Study Completion Date : | December 2023 |
For enrollment please visit www.clinicaltrials.gov.
